RHHVF:OTCMKTS
F. Hoffmann-La Roche
430,00 USD
arrow_upward
+0,41%(+1,78) 1 D.
10-05, 10:25:31 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „RHHVF“ įžvalgos...
Atidaryti
430,00 USD
Aukšta
430,00 USD
Žema
417,26 USD
Rinkos kapitalizacija
336,45 mlrd.
Vid. kiekis
5,21 tūkst.
Apimtis
345,00
52 sav. aukšta
490,33 USD
52 sav. žema
318,81 USD
Beta
0,51
Neapmokėtos akcijos
702,56 mln.
Darbuotojų skaičius
113 tūkst.
Atidaryti
430,00 USD
Aukšta
430,00 USD
Žema
417,26 USD
Rinkos kapitalizacija
336,45 mlrd.
Vid. kiekis
5,21 tūkst.
Apimtis
345,00
52 sav. aukšta
490,33 USD
52 sav. žema
318,81 USD
Beta
0,51
Neapmokėtos akcijos
702,56 mln.
Darbuotojų skaičius
113 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Euronext Markets: Real-time Stock Market Data | live
·
prieš 2 valandas
Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion
AD HOC NEWS
·
prieš 3 valandas
Roche reports enicepatide results. Roche Holding stock gains 1.27 percent
Stocktwits
·
prieš 11 valandų
Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist
Reuters
·
prieš 1 savaitę
Roche outlines plans to move towards autonomous AI labs
Profilis
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel.
Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.
The company owns the American biotechnology company Genentech, which is a wholly owned independent subsidiary, and the Japanese biotechnology company Chugai Pharmaceuticals, as well as the United States–based companies Ventana and Foundation Medicine. Roche's revenues during fiscal year 2020, were 58.32 billion Swiss francs. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights, with Swiss pharma firm Novartis owning a further third of its shares until 2021.
F. Hoffmann-La Roche is a full member of the European Federation of Pharmaceutical Industries and Associations. Wikipedia
Apie „F. Hoffmann-La Roche“
Generalinis direktoriusThomas Schinecker
Darbuotojai113 tūkst.
Įkurta1896-10-01
Pagrindinė būstinėBazelis, Bazelio miestas, Šveicarija
Sektorius-
Svetainėroche.com